Unveiling CXCR2 as a promising therapeutic target in renal cell carcinoma: exploring the immunotherapeutic paradigm shift through its inhibition by RCT001.

Christopher MontemagnoArnaud JacquelCharlotte PandianiOlivia RastoinRosie DawalibyThomas SchmittMaxence BourgoinHéliciane PalenzuelaAnne-Laure RossiDamien AmbrosettiJerome DurivaultFrederic LucianoDelphine BorchielliniJulie Le DuLeticia Christina Pires GonçalvesPatrick AubergerRachid BenhidaLisa KingetBenoit BeuselinckCyril RoncoGilles PagèsMaeva Dufies

Published in: Journal of experimental & clinical cancer research : CR (2024)

RCT001, by inhibiting CXCR2 through its unique mechanism, effectively suppresses ccRCC cell proliferation, angiogenesis, and M2 macrophage polarization. This optimization potentiates the efficacy of immunotherapy and holds promise for significantly improving the survival prospects of metastatic ccRCC patients.

Keyphrases

cell proliferation
renal cell carcinoma
end stage renal disease
signaling pathway
ejection fraction
newly diagnosed
chronic kidney disease
small cell lung cancer
endothelial cells
cell cycle
vascular endothelial growth factor
big data
cell migration
machine learning
artificial intelligence
pi k akt
wound healing